MedTrace Logo

Sustained Release Formulation of Somatropin (rDNA Origin)for Injection

NCT00600808 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2008-01-25

No results posted yet for this study

Summary

Annualised height velocity after 12/24 months treatment and HV SDS height velocity after 12/24 months treatment expressed as number of standard deviations difference from the mean population height velocity for the appropriate gender and chronological age.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

BPLG-003

Sponsors & Collaborators

  • LG Life Sciences

    collaborator INDUSTRY

  • BioPartners GmbH

    lead INDUSTRY

Principal Investigators

  • Ference Peter, MD · BUDA Children's Hospital, Budapest

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600808 on ClinicalTrials.gov